Streetwise Reports' Article Archives — Current Month (1)

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial (12/05/2022)

Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.

more>

More Archives

2022Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes